2023
1. Bornhauser M, Schliemann C, Schetelig J, Rollig C, Kramer M, Glass B, Platzbecker U, Burchert A, Hanel M, Muller LP, Klein S, Bug G, Beelen D, Rosler W, Schafer-Eckart K, Schmid C, Jost E, Lenz G, Tischer J, Spiekermann K, Pfirrmann M, Serve H, Stolzel F, Alakel N, Middeke JM, Thiede C, Ehninger G, Berdel WE, Stelljes M. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2023;9(4):519-526.
2. Donato E, Correia N, Andresen C, Karpova D, Wurth R, Klein C, Sohn M, Przybylla A, Zeisberger P, Rothfelder K, Salih H, Bonig H, Stasik S, Rollig C, Dolnik A, Bullinger L, Buchholz F, Thiede C, Hubschmann D, Trumpp A. Retained functional normal and preleukemic HSCs at diagnosis are associated with good prognosis in DNMT3AmutNPM1mut AMLs. Blood Adv. 2023;7(6):1011-1018.
3. Eckardt JN, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S, Sauer T, Scholl S, Hochhaus A, Crysandt M, Brummendorf TH, Krug U, Wormann B, Hiddemann W, Gorlich D, Sauerland C, Steffen B, Einsele H, Neubauer A, Burchert A, Schafer-Eckart K, Berdel WE, Schliemann C, Krause SW, Hanel M, Hanoun M, Kaufmann M, Fransecky L, Braess J, Ruhnke L, Schetelig J, Middeke JM, Serve H, Baldus CD, Platzbecker U, Muller-Tidow C, Bornhauser M, Herold T, Thiede C, Rollig C. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European LeukemiaNet risk classification. Leukemia. 2023;37(11):2282-2285.
4. Eckardt JN, Rollig C, Metzeler K, Heisig P, Stasik S, Georgi JA, Kroschinsky F, Stolzel F, Platzbecker U, Spiekermann K, Krug U, Braess J, Gorlich D, Sauerland C, Woermann B, Herold T, Hiddemann W, Muller-Tidow C, Serve H, Baldus CD, Schafer-Eckart K, Kaufmann M, Krause SW, Hanel M, Berdel WE, Schliemann C, Mayer J, Hanoun M, Schetelig J, Wendt K, Bornhauser M, Thiede C, Middeke JM. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles. Commun Med (Lond). 2023;3(1):68.
5. Eckardt JN, Rollig C, Metzeler K, Kramer M, Stasik S, Georgi JA, Heisig P, Spiekermann K, Krug U, Braess J, Gorlich D, Sauerland CM, Woermann B, Herold T, Berdel WE, Hiddemann W, Kroschinsky F, Schetelig J, Platzbecker U, Muller-Tidow C, Sauer T, Serve H, Baldus C, Schafer-Eckart K, Kaufmann M, Krause S, Hanel M, Schliemann C, Hanoun M, Thiede C, Bornhauser M, Wendt K, Middeke JM. Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning. Haematologica. 2023;108(3):690-704.
6. Eckardt JN, Stasik S, Rollig C, Petzold A, Sauer T, Scholl S, Hochhaus A, Crysandt M, Brummendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schafer-Eckart K, Schliemann C, Krause SW, Herbst R, Hanel M, Hanoun M, Kaiser U, Kaufmann M, Racil Z, Mayer J, Oelschlagel U, Berdel WE, Ehninger G, Serve H, Muller-Tidow C, Platzbecker U, Baldus CD, Dahl A, Schetelig J, Bornhauser M, Middeke JM, Thiede C. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia. Leukemia. 2023;37(12):2395-2403.
7. Eckardt JN, Stasik S, Rollig C, Sauer T, Scholl S, Hochhaus A, Crysandt M, Brummendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schafer-Eckart K, Schliemann C, Krause SW, Herbst R, Hanel M, Hanoun M, Kaiser U, Kaufmann M, Racil Z, Mayer J, Cerqueira T, Kroschinsky F, Berdel WE, Serve H, Muller-Tidow C, Platzbecker U, Baldus CD, Schetelig J, Siepmann T, Bornhauser M, Middeke JM, Thiede C. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome. Blood Cancer J. 2023;13(1):18.
8. Georgi JA, Stasik S, Eckardt JN, Zukunft S, Hartwig M, Rollig C, Middeke JM, Oelschlagel U, Krug U, Sauer T, Scholl S, Hochhaus A, Brummendorf TH, Naumann R, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, Schafer-Eckart K, Schliemann C, Krause SW, Hanel M, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Muller-Tidow C, Platzbecker U, Berdel WE, Serve H, Ehninger G, Bornhauser M, Schetelig J, Kroschinsky F, Thiede C, UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome. Blood Cancer J. 2023;13(1):88.
9. Heidenreich F, Falk B, Baldauf H, Massalski C, Schafer G, Rucker-Braun E, Altmann H, Sauter J, Solloch UV, Lange V, Stolzel F, Rollig C, Middeke JM, von Bonin M, Thiede C, Schafer-Eckart K, Muller-Tidow C, Krause SW, Kraus S, Kaufmann M, Hanel M, Serve H, Neubauer A, Bornhauser M, Schmidt AH, Schetelig J. Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia. Blood Adv. 2023;7(13):2994-3004.
10. Kayser S, Martinez-Cuadron D, Hanoun M, Stolzel F, Gil C, Reinhardt HC, Aguiar E, Schafer-Eckart K, Burgues JMB, Steffen B, Bernal T, Krause SW, Riaza R, Schliemann C, Cervera J, Kaufmann M, Torres-Minana L, Hanel M, Acuna-Cruz E, Jost E, Algarra JL, Crysandt M, Fransecky L, Cornago-Navascues J, Kraus S, Martinez-Lopez J, Einsele H, Niemann D, Neubauer A, Seggewiss-Bernhardt R, Scholl S, Klein SA, Schmid C, Schaich M, Schmidt-Hieber M, Zukunft S, Ho AD, Platzbecker U, Baldus CD, Muller-Tidow C, Thiede C, Bornhauser M, Serve H, Levis M, Montesinos P, Rollig C, Schlenk RF. Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4. Haematologica. 2023;108(1):34-41.
11. Kayser S, Martinez-Cuadron D, Rodriguez-Veiga R, Hanel M, Tormo M, Schafer-Eckart K, Botella C, Stolzel F, Del Castillo TB, Keller U, Rodriguez-Medina C, Held G, Amigo ML, Schliemann C, Colorado M, Kaufmann M, Garcia MB, Krause SW, Gorner M, Jost E, Steffen B, Zukunft S, Platzbecker U, Ho AD, Baldus CD, Serve H, Muller-Tidow C, Thiede C, Bornhauser M, Montesinos P, Rollig C, Schlenk RF. Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia. Haematologica. 2023;108(8):2059-2066.
12. Othman J, Meggendorfer M, Tiacci E, Thiede C, Schlenk R, Dillon R, Stasik S, Venanzi A, Bertoli S, Delabesse E, Dumas PY, Pigneux A, Bidet A, Gilkes AF, Thomas I, Voso MT, Rambaldi A, Brunetti L, Perriello VM, Andresen V, Gjertsen BT, Martelli MP, Recher C, Rollig C, Bornhauser M, Serve H, Muller-Tidow C, Baldus CD, Haferlach T, Russell N, Falini B. Overlapping features of therapy-related and de novo NPM1-mutated AML. Blood. 2023;141(15):1846-1857.
13. Ravandi F, Cloos J, Buccisano F, Dillon R, Dohner K, Freeman SD, Hourigan CS, Ossenkoppele GJ, Roboz GJ, Subklewe M, Thiede C, Arnhardt I, Valk PJM, Venditti A, Wei AH, Walter RB, Heuser M. Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel. Am J Hematol. 2023;98(12):1847-1855.
14. Ruhnke L, Rollig C, Herold S, Sauer T, Brandts CH, Steffen B, Schafer-Eckart K, Krause SW, Hanel M, Reichle A, Scholl S, Neubauer A, Mikesch JH, Schetelig J, Stolzel F, Kramer M, Haake A, Frimmel J, Kramer A, Schlenk R, Platzbecker U, Serve H, Baldus CD, Muller-Tidow C, Aust D, Bornhauser M, Ehninger G, Thiede C. Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3- ITD mutations: results of the SAL MIDOKIT trial. Haematologica. 2023;108(9):2520-2525.
15. Schneider M, Rolfs C, Trumpp M, Winter S, Fischer L, Richter M, Menger V, Nenoff K, Grieb N, Metzeler KH, Kubasch AS, Sockel K, Thiede C, Wu J, Woo J, Bruderle A, Hofbauer LC, Lutzner J, Roth A, Cross M, Platzbecker U. Activation of distinct inflammatory pathways in subgroups of LR-MDS. Leukemia. 2023;37(8):1709-1718.
16. Scott S, Dillon R, Thiede C, Sadiq S, Cartwright A, Clouston HJ, Travis D, Mokretar K, Potter N, Chantry A, Whitby L. Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study. Blood Adv. 2023;7(14):3686-3694.
17. Tober R, Schnetzke U, Fleischmann M, Yomade O, Schrenk K, Hammersen J, Glaser A, Thiede C, Hochhaus A, Scholl S. Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia. J Cancer Res Clin Oncol. 2023;149(4):1569-1583.
18. Zhou F, Aroua N, Liu Y, Rohde C, Cheng J, Wirth AK, Fijalkowska D, Gollner S, Lotze M, Yun H, Yu X, Pabst C, Sauer T, Oellerich T, Serve H, Rollig C, Bornhauser M, Thiede C, Baldus C, Frye M, Raffel S, Krijgsveld J, Jeremias I, Beckmann R, Trumpp A, Muller-Tidow C. A Dynamic rRNA Ribomethylome Drives Stemness in Acute Myeloid Leukemia. Cancer Discov. 2023;13(2):332-347.
